2020
Management strategies for human babesiosis
Smith RP, Hunfeld KP, Krause PJ. Management strategies for human babesiosis. Expert Review Of Anti-infective Therapy 2020, 18: 625-636. PMID: 32268823, DOI: 10.1080/14787210.2020.1752193.Peer-Reviewed Original Research
2019
Human babesiosis
Krause PJ. Human babesiosis. International Journal For Parasitology 2019, 49: 165-174. PMID: 30690090, DOI: 10.1016/j.ijpara.2018.11.007.Peer-Reviewed Original ResearchConceptsBurden of infectionSignificant health burdenNon-endemic areasTick-borne diseaseThin blood smearsBlood transfusionExchange transfusionHealth burdenSevere casesBlood smearsHuman babesiosisIntraerythrocytic parasitesTransfusionInfectionBabesiosisBurdenProtective measuresBabesia DNAClindamycinAzithromycinAtovaquoneDiseaseSmearsDiagnosis
2010
Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection
Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, Mittleman A, Aguero-Rosenfeld M, Topal J, Krause PJ. Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection. Clinical Infectious Diseases 2010, 50: 381-386. PMID: 20047477, DOI: 10.1086/649859.Peer-Reviewed Original ResearchConceptsDrug regimenB. microtiLevel of immunosuppressionBabesia microti infectionTreatment of babesiosisDrug-resistant strainsEmergence of resistanceActive babesiosisMicrobiologic relapseLaboratory abnormalitiesDrug regimensImmunocompromised patientsOptimal therapyTreatment failureDrug therapyMicroti infectionPatientsClinical case historiesDrug resistanceBabesia microtiInfectionRegimenMicrotiEventual developmentBabesiosis
2008
Human Babesiosis
Vannier E, Gewurz BE, Krause PJ. Human Babesiosis. Infectious Disease Clinics Of North America 2008, 22: 469-488. PMID: 18755385, PMCID: PMC3998201, DOI: 10.1016/j.idc.2008.03.010.Peer-Reviewed Original ResearchConceptsBabesial infectionHuman babesiosisCombination of atovaquoneTreatment of choiceSpecific laboratory diagnosisModerate illnessExchange transfusionPolymerase chain reactionSevere diseaseLaboratory diagnosisMorphologic examinationBlood smearsProtozoal parasitesInfectionChain reactionBabesial DNABabesiosisIntraerythrocytic infectionUnited StatesIxodid ticksTransfusionUpper midwestern regionsClindamycinSerologyAzithromycinPersistent and Relapsing Babesiosis in Immunocompromised Patients
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases 2008, 46: 370-376. PMID: 18181735, DOI: 10.1086/525852.Peer-Reviewed Original ResearchConceptsCase patientsAntibabesial treatmentClinical courseControl subjectsBlood smearsRetrospective case-control studyOptimal treatment regimenStandard antimicrobial therapyMalaria-like illnessBabesia microti infectionMost cases patientsCase-control studyCourse of therapyB-cell lymphomaAdministration of atovaquoneImmunologic statusStandard therapyAntimicrobial regimenSuch patientsTreatment regimenMicroti infectionAntimicrobial therapyPersistent infectionCell lymphomaAcute babesiosis
2007
ATOVAQUONE AND AZITHROMYCIN TREATMENT FOR BABESIOSIS IN AN INFANT
Raju M, Salazar JC, Leopold H, Krause PJ. ATOVAQUONE AND AZITHROMYCIN TREATMENT FOR BABESIOSIS IN AN INFANT. The Pediatric Infectious Disease Journal 2007, 26: 181-183. PMID: 17259886, DOI: 10.1097/01.inf.0000250622.11505.8f.Peer-Reviewed Original ResearchConceptsCyanotic heart diseaseBabesia microti infectionTreatment of childrenOral azithromycinThin blood smearsInitial presentationSevere anemiaHeart diseaseMicroti infectionPolymerase chain reactionHepatic enzymesBlood smearsInfantsIntraerythrocytic parasitesChain reactionTreatmentBabesiosisLaboratory testsFebrileThrombocytopeniaCyanoticAnemiaClindamycinSerologyAzithromycin
2003
Babesiosis in Pregnancy
Feder HM, Lawlor M, Krause PJ. Babesiosis in Pregnancy. New England Journal Of Medicine 2003, 349: 195-196. PMID: 12853599, DOI: 10.1056/nejm200307103490221.Peer-Reviewed Original Research
2000
Atovaquone and Azithromycin for the Treatment of Babesiosis
Krause P, Lepore T, Sikand V, Gadbaw J, Burke G, Telford S, Brassard P, Pearl D, Azlanzadeh J, Christianson D, McGrath D, Spielman A. Atovaquone and Azithromycin for the Treatment of Babesiosis. New England Journal Of Medicine 2000, 343: 1454-1458. PMID: 11078770, DOI: 10.1056/nejm200011163432004.Peer-Reviewed Original ResearchConceptsCommon adverse effectsTreatment of babesiosisAdverse reactionsAdverse effectsCourse of clindamycinRegimen of clindamycinStart of therapyMalaria-like illnessPromising alternative treatmentStandard treatmentAlternative treatmentRegimenClindamycinAzithromycinAtovaquoneMonthsDiarrheaTreatmentBabesiosisQuinineSymptomsSubjectsPercentDaysBabesia microti DNA
1998
Persistent Parasitemia after Acute Babesiosis
Krause P, Spielman A, Telford S, Sikand V, McKay K, Christianson D, Pollack R, Brassard P, Magera J, Ryan R, Persing D. Persistent Parasitemia after Acute Babesiosis. New England Journal Of Medicine 1998, 339: 160-165. PMID: 9664092, DOI: 10.1056/nejm199807163390304.Peer-Reviewed Original ResearchConceptsDuration of parasitemiaSpecific therapySide effectsInfected peopleCommunity-based studyEpisodes of illnessProtozoan Babesia microtiBabesial DNASymptoms of babesiosisRecrudescent diseaseQuinine therapyThin blood smearsPersistent parasitemiaInfected subjectsSerologic testsIll subjectsSpecific symptomsAcute babesiosisMore monthsParasitemiaBlood smearsBabesial infectionTherapyBabesia microtiSymptoms